| Expression pattern: |
DS |
| Associated gene: |
FOXO3 |
| Associated microRNA: |
miR-193b-5p |
| Biological function: |
May modulate metabolic dysfunction and NASH pathogenesis; may influence lipogenesis, inflammation, apoptosis, glucose metabolism, insulin resistance, and cytoprotective/anti-inflammatory functions through regulation of miR-193b-5p. |
| Molecular mechanism: |
circ-MYO9B directly targets and regulates/sponges miR-193b-5p, potentially affecting FOXO3 and metabolic pathways related to lipogenesis, inflammation, apoptosis, and glucose metabolism. |
| Biological pathway or process: |
lipid metabolism (other); inflammation (other); apoptosis (other); glycolysis (other); NF-kappaB (other); AMPK (other); ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Luciferase Reporter Assay; Transfection; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Potential diagnostic biomarker and therapeutic target for NASH/NASH-CH; ROC analysis suggested diagnostic potential in blood and liver tissue. |
| Description: |
This study reports that circ-MYO9B is dysregulated in NASH-CH, with upregulation in liver tissue and downregulation in blood. circ-MYO9B directly interacts with and regulates hsa-miR-193b-5p, potentially influencing FOXO3-related and metabolic processes including lipogenesis, inflammation, apoptosis, and glucose metabolism. The authors propose circ-MYO9B as a potential diagnostic biomarker and therapeutic target, although functional validation in hepatocyte models remains needed. |
| Confidence score: |
0.6986 |